This is going to be a very important sort of transition time as we move from vaccinating the people who are at highest risk of get of it’s being exposed to the virus or having the severest symptoms from the virus. As we move to genera to vaccinating the general population, we’re going to have to increase our effectiveness and efficiency in which we’re vaccinating, because now is the time we can utilize things like mass vaccination centers to get the vaccine out to as many people as possible. With the new variants emerging with covet cases decreasing, but still at levels that are way too high for us to handle in terms of our medical infrastructure, it’s important for us to get as many people vaccinated as quickly as possible to help turn this corner. France doesn’t have enough doses, but they also have maybe a bigger problem of people not wanting to get vaccinated, what’s the us like in terms of anti vaxxers. Well, you know it certainly seems that over the past few weeks of the vaccination campaign, some polls have shown that there’s been an increase in terms of the willingness of americans to get the vaccine that’s. A good sign we’d still like to see those numbers to be even higher than they are right now, but i think that what we can take from the roll out of the vaccine is that these vaccines are safe. We haven’t seen any signatures uh different from what was seen in the clinical trials in terms of safety, and certainly, as studies are coming out now, looking at the efficacy of of these vaccines, they induce really strong immune responses that appear to be very good at limiting Virus replication, so everything looks good with the vaccine roll out so far and i think that’s stoking some confidence in the u.
s population. I feel it here. Certainly dr peckhouse just so you know: i’ll have my second shot here at 11 a.m. This morning, looking forward to that folks, thanks to nyu langone for great service, dr peckos uh, the marvin martin index indic, the former u.s ambassador to israel, notes the times of israel with the statistics on what israel has learned: zero deaths and only four severe cases among 523 thousand fully vaccinated israelis what’s the best practice. Israel is doing that. We need to do well. You know they were highly efficient at rolling out their vaccine, not only to the high risk groups, but also into the general population, and i think, that’s the lesson to be learned from here and the and the the rapid downtick in terms of severe and cases and Hospitalizations and deaths is probably the most important thing that vaccines give us that protection and as the more efficiently you can roll this out. The sooner you’ll see those effects. I i know we’re on a network of delicacies here, but let me cut to the chase. Why can’t america do that? We put somebody on the moon. Why can’t? We replicate the best practices of israel yeah partially. I think this is a leadership issue. We need to have more centralized leadership, more clear plans in terms of how people get vaccines and how to sign up for them and how to distribute them right now. Certain states are doing a good job of that.
Other states are so decentralized that people have to call 10 or 12 places to get on lists to hopefully get a vaccine and that’s not efficient, so centralized leadership. Centralized guidance in terms of how to roll this out would go a long way to make these rollouts more efficient in different states. How many um andrew peck variants are there out there and you know the more we do genome sequencing? Are we going to find many more variants that could not be? You know, taken care of by these vaccines yeah, as we do more sequencing, we see lots of variants out there. This is not unexpected. This is a virus that mutates on a regular basis. I and others are trying to lump these now into variance versus variants of concern, and those variants of concern are ones that have mutations in places that we know affect the function of the virus. So we have three major classes: the south african, the brazil and the uk variants, and then other minor ones are emerging that are still of that are of concern because of the mutations that they have. These mutations can increase transmission or they can make the virus a little less sensitive to antibodies that were induced by the vaccine or infection and that’s. Why we consider them variants of concern they’re still sensitive to the vaccines. So this doesn’t mean that we should stop our vaccination progress.